Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human MPL Antibodies:
anti-Mouse (Murine) MPL Antibodies:
anti-Rat (Rattus) MPL Antibodies:
Go to our pre-filtered search.
Human Monoclonal MPL Primary Antibody for FACS, WB - ABIN967682
Broudy, Lin, Fox, Taga, Saito, Kaushansky: Thrombopoietin stimulates colony-forming unit-megakaryocyte proliferation and megakaryocyte maturation independently of cytokines that signal through the gp130 receptor subunit. in Blood 1996
Show all 4 Pubmed References
Human Monoclonal MPL Primary Antibody for FACS, ELISA - ABIN969542
Marty, Chaligné, Lacout, Constantinescu, Vainchenker, Villeval: Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity. in The Journal of biological chemistry 2009
Show all 2 Pubmed References
Human Polyclonal MPL Primary Antibody for IF (p) - ABIN2177733
Maekawa, Osawa, Izumi, Nagao, Takano, Okada, Tachi, Teramoto, Kawamura, Horiuchi, Saga, Kato, Yamamura, Watanabe, Kobayashi, Kobayashi, Sato, Hashimoto, Suzu, Kimura: Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis. in Leukemia 2017
Results show that mutant CALR (show CALR Antibodies) induces autocrine, but not paracrine activation of MPL in myeloproliferative neoplasm. [review]
these results demonstrate that MPL P106L is a receptor with an incomplete defect in trafficking.
Coexisting mutations of the JAK2 (show JAK2 Antibodies), CALR (show CALR Antibodies), and MPL genes in myeloproliferative neoplasms suggest that CALR (show CALR Antibodies) and MPL should be analyzed not only in JAK2 (show JAK2 Antibodies)-negative patients but also in low V617F mutation patients.
identification of a higher frequency of co-existing JAK2 (show JAK2 Antibodies) exon-12 or MPL exon-10 mutations in patients with myeloproliferative neoplasms with a low JAK2V617F allelic burden compared to those with a higher allelic burden.
A newborn girl with congenitcal amegakaryocytic thrombocytopenia had a homozygous missense Trp154-to- Arg mutation in exon 4 of c-MPL. The same heterozygote mutation was detected in her mother, father, and 2 siblings.
Mutation status of JAK2 (show JAK2 Antibodies), CALR (show CALR Antibodies), and MPL in essential thrombocythemia and primary myelofibrosis defines clinical outcome.
Normal FLT3 (show FLT3 Antibodies) and negative expression of CD34 (show CD34 Antibodies) and cMPL may predict a longer overall survival in aute myeloid leukemia (show BCL11A Antibodies).
we show that the positive charge of the CALR (show CALR Antibodies) mutant C-terminus is necessary to transform hematopoietic cells by enabling binding between mutant CALR (show CALR Antibodies) and the thrombopoietin receptor MPL.
Anagrelide proved effective among all molecular subsets, indicating that JAK2 (show JAK2 Antibodies)/CALR (show CALR Antibodies)/MPL mutational status does not seem to represent a major determinant of choice of cytoreductive treatment among essential thrombocythemia therapies.
In essential thrombocythemia, MPL mutations might be associated with a higher risk of fibrotic transformation and the presence of JAK2 (show JAK2 Antibodies)/MPL mutations with higher risk of thrombosis.
C-Mpl is expressed on osteoblasts and osteoclasts and is important in regulating skeletal homeostasis.
CALR (show CALR Antibodies) mutants are sufficient to induce thrombocytosis through MPL activation.
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin (show CALR Antibodies) mutants.
The interaction between Mpl and Atp5d (show ATP5D Antibodies) was confirmed by the yeast two-hybrid system, mammalian two-hybrid assay, pull-down experiment, and co-immunoprecipitation study in vivo and in vitro.
Mouse prenatal platelet-forming lineages share a core transcriptional program but divergent dependence on MPL.
MERIT40 (show BABAM1 Antibodies) deficiency triggers hypersensitivity to Tpo (show THPO Antibodies) stimulation and the stem cell phenotypes are abrogated on a background null for the Tpo (show THPO Antibodies) receptor Mpl.
OTT1 regulates the alternative splicing of Mpl-TR, a truncated isoform of c-Mpl, which modulates Thrombopoietin (show THPO Antibodies)-mediated signaling.
Mpl expression, but not Tpo (show THPO Antibodies), is fundamental in the development of JAK2V617F(+) myeloproliferative neoplasms
Thrombopoietin (show THPO Antibodies)/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 (show MECOM Antibodies) leukemia.
In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated.
, myeloproliferative leukemia virus oncogene
, thrombopoietin receptor-like
, myeloproliferative leukemia protein
, proto-oncogene c-Mpl